Source Paper
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence et al.
Journal of Clinical Investigation • 1999
Nonhuman Primate Toxicity Study
Objective: Evaluation of tissue and organ toxicity following repeated intravenous Apo2L (TRAIL) injections in nonhuman primates to assess safety profile for potential cancer therapy
This is a Nonhuman Primate Toxicity Study protocol using nonhuman primates as the model organism. The procedure involves 3 procedural steps, 1 materials. Extracted from a 1999 paper published in Journal of Clinical Investigation.
Model and subjects
nonhuman primates • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Preparation of Apo2L protein • Repeated intravenous injections in nonhuman primates • Tissue and organ examination
Primary readouts
- Tissue toxicity assessment
- Organ toxicity assessment
- Detectable adverse effects to normal tissues
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Preparation of Apo2L protein
Generate recombinant soluble version of native human Apo2L protein in bacterial expression system
Note: Protein must be potently active for subsequent injections
View evidence from paper
“we generated in bacteria a potently active soluble version of the native human protein”
Repeated intravenous injections in nonhuman primates
Administer repeated intravenous injections of Apo2L to nonhuman primates
Note: Injection schedule and dosage not explicitly detailed in provided text
View evidence from paper
“Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined”
Tissue and organ examination
Examine tissues and organs for signs of toxicity following Apo2L treatment
Note: Specific tissues and organs examined not detailed in provided text
View evidence from paper
“Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined”